MK-2870-023

About this trial

Sacituzumab Tirumotecan is an antibody drug conjugate (ADC). This ADC works by binding to a protein called TROP2 which is often overexpressed on various tumour types. When it is binded to the TROP2 protein it acts as a delivery system. The antibody brings a chemotherapy directly to cancer cells that express TROP2. In this study, all patients will receive four cycles of Pembrolizumab, Carboplatin, Paclitaxel, or Nabpaclitaxel as their initial treatment. They will then receive either Pembrolizumab (Control Arm) or Pembrolizumab and Sacituzumab Tirumotecan (Experimental Arm) as maintenance treatment. Maintenance treatment is ongoing therapy given to patients after their initial treatment to help keep their cancer from returning or progressing. Patients who are eligible to participate in this study will be assigned by chance (one chance in two) to one of two treatment groups via a process called randomisation.

Patient Profile

Patients with Metastatic Squamous Non-Small Cell Lung Cancer

Where’s this trial being run?

St James’s Hospital

Can I join this study / trial?

The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.

It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	MK-2870-023
Number:	24-107
Full Title:	Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan(Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Principal Investigator:	Dr Sinead Cuffe
Type:	Industry Sponsored
Sponsor:	MSD
Recruitment Started:	Global: Ireland: Feb 2025

Global Recruitment Target:	851
Ireland Recruitment Target:	4